LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023

January 06, 2023 | Last Trade: US$57.17 0.28 0.49

BOSTON, Jan. 6, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, February 7, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 7, 2023.

The call can be accessed via teleconference at: Q3 2023 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/m6/p/qyrbnnof https://edge.media-server.com/mmc/p/pt8ugsbv 

A replay of the conference call and webcast will be available for one year beginning on February 7, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contact: 
Olga Guyette, Sr. Director, Investor Relations & Treasury
(781) 356-9763
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Josh Gitelson, Director, Global Communications
(781) 356-9776
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page